HK1221147A1 - 使用黑素皮質素治療胰島素敏感性 - Google Patents

使用黑素皮質素治療胰島素敏感性

Info

Publication number
HK1221147A1
HK1221147A1 HK16109223.2A HK16109223A HK1221147A1 HK 1221147 A1 HK1221147 A1 HK 1221147A1 HK 16109223 A HK16109223 A HK 16109223A HK 1221147 A1 HK1221147 A1 HK 1221147A1
Authority
HK
Hong Kong
Prior art keywords
melanocortins
insulin sensitivity
treat insulin
treat
sensitivity
Prior art date
Application number
HK16109223.2A
Other languages
English (en)
Inventor
Heather A Halem
Michael Dewitt Culler
Andrew A Butler
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1221147A1 publication Critical patent/HK1221147A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK16109223.2A 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性 HK1221147A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
HK1221147A1 true HK1221147A1 (zh) 2017-05-26

Family

ID=40626385

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11100510.8A HK1146242A1 (zh) 2007-11-05 2011-01-19 使用黑素皮質素治療胰島素敏感性
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用
HK16109223.2A HK1221147A1 (zh) 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK11100510.8A HK1146242A1 (zh) 2007-11-05 2011-01-19 使用黑素皮質素治療胰島素敏感性
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用

Country Status (21)

Country Link
US (6) US9155777B2 (zh)
EP (2) EP2214693B1 (zh)
JP (3) JP2011502987A (zh)
KR (3) KR101662044B1 (zh)
CN (2) CN103316345B (zh)
AR (1) AR069461A1 (zh)
AU (1) AU2008325194B2 (zh)
BR (1) BRPI0819188B1 (zh)
CA (2) CA2704651C (zh)
DK (1) DK2214693T3 (zh)
ES (2) ES2555522T3 (zh)
HK (3) HK1146242A1 (zh)
HU (1) HUE026842T2 (zh)
IL (2) IL205554A (zh)
NZ (1) NZ585131A (zh)
PL (1) PL2214693T3 (zh)
PT (2) PT2979703T (zh)
RU (1) RU2453328C2 (zh)
TR (1) TR201815292T4 (zh)
TW (1) TWI374030B (zh)
WO (1) WO2009061411A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147556A2 (en) * 2007-05-25 2008-12-04 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR20120059520A (ko) * 2009-08-05 2012-06-08 입센 파마 에스.에이.에스 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도
WO2011026015A2 (en) * 2009-08-31 2011-03-03 Gruber Kenneth A Stabilized melanocortin ligands
CN102665401A (zh) 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
CA2781405A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
HUE056948T2 (hu) 2011-12-29 2022-04-28 Rhythm Pharmaceuticals Inc Melanokortin-4 receptorral összefüggõ rendellenességek kezelési módszere heterozigóta hordozókban
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
PT2970389T (pt) 2013-03-15 2020-10-21 Rhythm Pharmaceuticals Inc Composições farmacêuticas
JP6622690B2 (ja) 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (en) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
CA2998862A1 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CA3102603A1 (en) 2018-06-05 2019-12-12 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
EP1322954A4 (en) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst METHOD FOR TREATING INSULIN RESISTANCE IN OVERWEIGHT AND DIABETES
MXPA04011557A (es) * 2002-05-23 2005-07-05 Chiron Corp Compuestos de quinazolinona sustituida.
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
CA2519939A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
AU2004235872A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
KR20060014444A (ko) * 2003-06-19 2006-02-15 일라이 릴리 앤드 캄파니 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
EP1732586A1 (en) * 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
WO2006049933A2 (en) * 2004-10-29 2006-05-11 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
AU2006269321A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
EP2236151B1 (en) * 2005-07-08 2012-05-23 Ipsen Pharma Melanocortin receptor ligands
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2008147556A2 (en) * 2007-05-25 2008-12-04 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
TW200848424A (en) 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
RU2453328C2 (ru) * 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
KR20120059520A (ko) 2009-08-05 2012-06-08 입센 파마 에스.에이.에스 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도

Also Published As

Publication number Publication date
US9155777B2 (en) 2015-10-13
ES2555522T3 (es) 2016-01-04
EP2979703B1 (en) 2018-07-18
CA2952095C (en) 2020-02-18
CN101980717A (zh) 2011-02-23
BRPI0819188B1 (pt) 2021-06-22
PL2214693T3 (pl) 2016-03-31
US20100311647A1 (en) 2010-12-09
RU2010122897A (ru) 2011-12-20
CN103316345B (zh) 2016-05-18
EP2214693A2 (en) 2010-08-11
HK1184692A1 (zh) 2014-01-30
PT2214693E (pt) 2015-12-07
EP2214693B1 (en) 2015-09-09
TWI374030B (en) 2012-10-11
DK2214693T3 (en) 2015-11-30
CA2704651C (en) 2017-03-07
US20220339239A1 (en) 2022-10-27
JP2013144690A (ja) 2013-07-25
KR20130065725A (ko) 2013-06-19
KR101290623B1 (ko) 2013-08-07
RU2453328C2 (ru) 2012-06-20
AU2008325194B2 (en) 2012-04-19
CA2952095A1 (en) 2009-05-14
NZ585131A (en) 2012-10-26
EP2979703A1 (en) 2016-02-03
WO2009061411A3 (en) 2010-04-15
ES2690556T3 (es) 2018-11-21
AU2008325194A1 (en) 2009-05-14
HK1146242A1 (zh) 2011-05-27
IL249998B (en) 2018-07-31
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
JP5964767B2 (ja) 2016-08-03
IL205554A (en) 2017-01-31
CA2704651A1 (en) 2009-05-14
AR069461A1 (es) 2010-01-27
TR201815292T4 (tr) 2018-11-21
US9439943B2 (en) 2016-09-13
US9827286B2 (en) 2017-11-28
PT2979703T (pt) 2018-10-31
EP2214693A4 (en) 2012-04-11
US20160354429A1 (en) 2016-12-08
HUE026842T2 (en) 2016-08-29
JP2011502987A (ja) 2011-01-27
BRPI0819188A2 (pt) 2015-09-01
KR20150013339A (ko) 2015-02-04
US20150366934A1 (en) 2015-12-24
CN103316345A (zh) 2013-09-25
WO2009061411A2 (en) 2009-05-14
IL205554A0 (en) 2010-12-30
US20190111105A1 (en) 2019-04-18
JP2015131827A (ja) 2015-07-23
US20180303899A1 (en) 2018-10-25
TW200932258A (en) 2009-08-01
IL249998A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
HK1221147A1 (zh) 使用黑素皮質素治療胰島素敏感性
IL213596A0 (en) Heterocyclic compounds and methods of use
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (zh) 化合物和使用方法
HK1154054A1 (en) Predictors of patient response to treatment with egf receptor inhibitors
IL208354A0 (en) Methods of treatment
GB0707750D0 (en) Treatment of organic matter
HK1160925A1 (zh) 組織蛋白酶 的用途
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB2448592B (en) Improvements to coffins
EP2470020A4 (en) BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
GB0723100D0 (en) Treatment of HFnEF
EP2066171A4 (en) ADMINISTERING A TREATMENT SUBSTANCE TO POROUS ELEMENTS
HK1156250A1 (zh) 阿帕地松單位劑量
GB0814296D0 (en) Improvements to coffins
GB0802903D0 (en) Treatment of diabetes
GB0801958D0 (en) Improvements relating to electro-optical sensors and their use
IL190834A0 (en) Improvements to bandages
GB0816217D0 (en) Treatment of hepatitis C
HU0800656D0 (en) Effective use of tea-composition
GB0809469D0 (en) Improvements relating to body jewelry
FI20080503A0 (fi) MSM-elementtien pintakäsittely
GB0717139D0 (en) Treatment of hepatitis C
GB0719334D0 (en) Improvements relating to electro-optical sensors and their use